A Phase II Study Assessing the Addition of Duvelisib or CC-486 to the Usual Treatment for Peripheral T-Cell Lymphoma

Full Title

A Randomized Phase II Study of CHO(E)P vs CC-486-CHO(E)P vs Duvelisib-CHO(E)P in Previously Untreated CD30 Negative Peripheral T-cell Lymphomas (A051902) (CIRB)

Purpose

The purpose of this study is to compare the safety and effectiveness of adding duvelisib or CC-486 (oral azacitidine) to the usual chemotherapy (cyclophosphamide, doxorubicin, vincristine, etoposide, and prednisone) in people with peripheral T-cell lymphoma. Duvelisib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth; it is taken orally (by mouth).

Participants will be randomly assigned to receive either:

• Duvelisib plus chemotherapy
• CC-486 plus chemotherapy
• Chemotherapy alone